Medicine Affordability, Mental Health And Opioid Abuse Rank As Toughest Global Health Challenges, New Report Says

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- A new global healthcare report finds that medicine affordability, mental health and continued opioid abuse stand as the toughest challenges to global health today. The findings are part of Kantar Health's 2018 edition of The Global Health and Wellness Report (GHWR), a comprehensive, patient-centric examination of global healthcare that provides unique insights on the most pressing health challenges facing populations in the United States, the EU5, Japan, and the key growth markets of China, Brazil and Russia.

The 2018 GHWR, now covering more than 3 million patient survey responses on the true impact of approximately 200 health conditions and thousands of sub-segments, reveals that:

• 1 in 5 U.S. patients report not filling a prescription due to cost.
• Chinese prescription drug use dramatically fell between 2009 and 2017 in favor of cost-saving, traditional Chinese medicine.
• Opioid use increased in 27 U.S. states from 2011 to 2017.
• Rates of U.S. adults contemplating suicide has dramatically risen from 2011 to 2017.
• The U.K. and U.S. rank highest in adults reporting depression.
• Mental illness in China and Japan is not discussed openly due to strong social stigmas.

"Each year certain dynamics take shape as key influencers of global health, and in 2018, our research points to five pillars around which the most impactful issues affecting global health and wellness are coalescing today," said Kantar Health's Michael Fronstin, General Manager, Real World Evidence. "Patients, employers and payers, as well as key industry stakeholders such as healthcare companies, patient advocacy groups and governmental agencies, will find great value in the scope and depth of our Global Health and Wellness Report, as it provides a better understanding of the magnitude of diseases and can be exploited to improve health-related outcomes around the world."

Five Pillars Impacting Global Health

• AFFORDABILITY ? Affordability continues to be a globally dominant issue as governments and private payers are challenged to provide patients appropriate access to effective treatments while balancing the costs of those therapies. Payers are pushing manufacturers for more evidence to support reimbursement, which often includes a combination of real-world evidence focused on unmet medical need and/or patient registries and comparative effectiveness studies.
  
  Patients are also taking a stand and implementing their own cost saving strategies, which can be dangerous as non-compliance can reduce efficacy and speed up disease progression. In fact, about one in five patients in the United States report having chosen not to refill a prescription at some point due to cost. The United States ranks highest in this category compared with the EU5, Japan and Brazil. U.S. patients are most likely to employ cost savings strategies such as:
  
  
• Taking less medicine than prescribed,
• Cutting tablets in half,
• Not filling a prescription because it was too expensive,
• Not filling a prescription and using an OTC medicine to save money,
• Buying a prescription less often than directed
  

In China, GHWR data indicates that there's been a significant drop in prescription medicine use for a variety of diseases and conditions, including pain, insomnia, Irritable Bowel Syndrome (IBS) and osteoporosis. We believe this can be attributed to many factors, including patients purchasing more medications over the counter, less attentive physicians, and an effort by patients to take control of their health.

• PAIN ? While overall U.S. prescription opioid use peaked in 2011 and has trended downward since, 27 U.S. states actually experienced an increase in opioid use from 2011 to 2017. What's more, Kantar Health research indicates that working class communities have been the most vulnerable, as these communities are failing to respond to anti-opiate messaging. Thus, opiates are thriving in communities that do not thrive.

For example, in New Jersey, Kantar Health research indicates that opiate use is linked to income, education and employment. For income, we found that more than two times as many opioid users in New Jersey have a household income of < $25,000 versus those who do not use opioids. Additionally, opioid users are more likely to be non-college grads, unemployed, and are four times more likely to be on disability.

• MENTAL ILLNESS ? Given the recent high-profile suicides of Kate Spade, Anthony Bourdain, and singers Avicii and Kim Jonghyun, we found that there's been a renewed global focus on mental health. However, in Asian countries such as Japan and China, our research indicates that there is still a strong stigma associated with mental illness that prevents it from being discussed openly. For example, in China, nearly twice as many adults are symptomatic of depression, 3.5 percent, compared with those actually diagnosed, 1.9 percent.

Meanwhile, in the United States, there's been a precipitous spike in the number of Americans considering suicide ? including those having alarming thoughts of "I would be better off dead" for several days, for more than half the days, or nearly every day. Similarly, in the United States and the EU5, the self-reported rates for overall mental health conditions have increased, but these increases have not carried over to the diagnosis rates. In fact, the United States and UK have the highest percentage of adults who have self-reported that they have experienced depression, with the United States registering at 28 percent and the UK registering at 26 percent.

• HEALTH TECH ? Individuals today are taking more accountability for their health decisions and increasingly dictating how the healthcare industry operates. Since 2015, the use of health-related apps has increased 25%, while the use of wearable technology has increased 12.3%. Today, 21% of American adults report owning an mHealth device for the purpose of monitoring their health or fitness. There has also been a rise in telemedicine, with 4.8 million U.S. adults having used telemedicine in the past year ? marking a 35% increase since 2017.

However, we believe there are barriers to wider adoption, as 47% of patients say that they are concerned about their health and fitness data being securely stored online, and 23% say that web connected devices are too complicated for them to use. Additionally, patient awareness of mHealth devices is another key barrier, with 59% of patients with diabetes saying that they're unfamiliar with web-connected glucose monitoring systems that connect wirelessly with a smartphone, and 66% of patients with heart conditions saying that they're unfamiliar with web-connected wireless blood pressure monitors.

• GROWTH MARKETS ? While the healthcare growth markets share some of the same challenges as mature healthcare markets ? namely rising healthcare costs, affordable access to medicines and costly chronic conditions ? there are pronounced differences in each of these growth countries that necessitate the need for comprehensive, market-specific plans to achieve success.

In China, the government is focusing on oncology and the treatment of chronic conditions given their significant impact on the population; and, while China is still largely a generics market, it's attempting to accelerate its approval process for innovative medicines. Additionally, Brazil is another strong healthcare growth market that features a unique public-private system, offering many opportunities for pharma companies to grow their brands and launch new medicines. Capitalizing on new technology and innovation in these and other growth markets will result from companies working to differentiate their innovative medicines and defend the value of their offerings.

"In order to improve global healthcare, we need to listen to the voice of the patient on the true impact of the diseases and conditions affecting them," Fronstin said. "While this is the 20-year anniversary of our National Health and Wellness Survey, the driver of the GHWR and the largest general population study based on primary research, we're most proud of the fact that this research continues to provide global healthcare stakeholders with the granular information they need to positively affect change."

To download Kantar Health's new GHWR, please visit www.kantarhealth.com.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.

SOURCE Kantar Health